IEIvet Etchegaray-Morales

Ivet Etchegaray-Morales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ivet Etchegaray-Morales has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Spatial distribution of long-term ultrafine particle concentrations and systemic lupus erythematosus burden in central Mexico

    by Jesús Guerrero-Morales, Ivet Etchegaray-Morales, Pamela Munguía-Realpozo, Raquel Hinojosa-Reyes, Claudia Mendoza-Pinto, Socorro Méndez-Martínez

  • Burden and temporal trends attributable to low bone mineral density in Mexico, 1990–2023: a global burden of disease analysis

    by Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Edith Ramírez-Lara, Miguel Ángel Saavedra-Salinas, Elizabeth Suárez-Belmont, Gustavo López-Gasca, Jorge Ayón-Aguilar, Máximo Alejandro García-Flores

  • Nationwide analysis of childhood-onset systemic lupus erythematosus mortality in Mexico, 2000–2023

    by Ivet Etchegaray-Morales, Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Diana Molina-Vélez, Juan Eugenio Hernández-Ávila, Edith Ramírez-Lara, Alfonso Ragnar Torres-Jiménez, Ángel David Osorio-Peña, Socorro Méndez-Martínez

    Objective: To evaluate national and regional trends in age-standardized mortality rates (ASMRs) from childhood-onset systemic lupus erythematosus (cSLE) in Mexico between 2000 and 2023, stratified by sex and region. Methods: This cross-sectional, retrospective study used the INEGI national death registry via the Public Health Intelligence Unit (UISP-INSP). Deaths in children aged 1–14 years attributed to cSLE were identified using ICD-10 codes M32.1, M32.8, and M32.9, excluding M32.0. ASMRs per 100,000 population were calculated using the 2010 Mexican census as a reference. Trends by year, sex, and region were analyzed using Poisson regression models with log link and population offset. Incidence rate ratios (IRRs) with 95% confidence intervals were estimated. Results: From 2000 to 2023, 637 cSLE deaths were recorded among 280,334 child deaths. Females accounted for 80.4% (ASMR 0.13; 95% CI 0.12–0.15), nearly fourfold higher than males (0.03; 95% CI 0.03–0.04). Although the Central and Midwest regions concentrated over 60% of total deaths, ASMRs were similar across regions (range 0.08–0.09 per 100,000). No consistent temporal trend in mortality was observed. Poisson regression confirmed significantly lower mortality in boys compared to girls (IRR 0.24; 95% CI 0.19–0.29; p < 0.001) with no statistically significant regional differences. Conclusions: cSLE mortality in Mexico has remained stable over time, with a marked female predominance. The regional distribution of deaths likely reflects population density rather than major differences in mortality risk. Strengthening early diagnosis, paediatric rheumatology care networks, and national surveillance systems is essential to reduce disease burden.

  • Limited Access to Systemic Lupus Erythematosus: A Systematic Review

    by Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Edith Ramírez-Lara, Juan Carlos Solis-Poblano, Jorge Ayón-Aguilar, Socorro Méndez-Martínez, Gabriela Medina Valeriano, Máximo Alejandro García Flores

    Introduction:: Inequities in systemic lupus erythematosus (SLE) care affect outcomes (i.e., flares, damage, mortality), interventions (referrals, advanced therapies), and populations (gender, race/ethnicity, and geographic region). This systematic review highlights themes related to access to care for SLE patients and explores potential solutions to address these disparities. Methods:: In adherence to PRISMA guidelines, we conducted a systematic review of the literature. We searched for articles published in PubMed, Scopus, Web of Science, Cochrane Library, and EBSCO. Publications related to economic burden, barriers and facilitators to access, and potential solutions were included. Results:: A total of 77 articles were identified. Five critical issues concerning access to SLE care were revealed from the literature: (1) economic burden, (2) barriers and facilitators to access, (3) utilization, (4) adherence, and (5) possible solutions to improve healthcare access. Discussion:: The usual barriers and facilitators involved several social factors related to health (i.e., transportation, insurance, and limited access to mental health services, among others). Utilization of SLE care is influenced by socioeconomic status (SES), ethnicity, and education level. Factors like low education, low SES, rural residency, and depressive symptom adherence contribute to nonadherence. There were various proposals to improve access to SLE care, including peer support, digital platforms (e.g., telemedicine), and community-based programs (such as PALS and WELL). Conclusions:: The SLE care field highlights the inequalities that impact marginalized communities. Emphasizing community-based programs, addressing social determinants of health, acknowledging social exclusion, and adopting digital platforms can help reduce healthcare inequity.

  • Influence of frailty syndrome on disease outcomes in systemic lupus erythematosus: a systematic review and narrative synthesis

    by Laura Serrano-Vertiz, Pamela Munguía-Realpozo, Claudia Mendoza-Pinto, Ivet Etchegaray-Morales, Edith Ramírez-Lara, Jorge Ayón-Aguilar, Socorro Méndez-Martínez

    To synthesize evidence on how frailty in adults with systemic lupus erythematosus (SLE) is measured and to evaluate its associations with major clinical and patient-centered outcomes. We conducted a PROSPERO-registered systematic review (CRD42024600473) following PRISMA guidelines. PubMed, Scopus, Web of Science, and EBSCO were searched from inception to July 2025. Observational studies assessing frailty in adults with SLE and reporting prevalence and/or associations with organ damage, healthcare utilization, mortality, disability, or health-related quality of life (HRQoL) were included. Owing to heterogeneity in definitions and outcomes, findings were synthesized narratively. Seventeen studies were included. Frailty was measured using deficit-accumulation indices (e.g. the SLICC-Frailty Index), phenotype-based definitions (e.g. the Fried Phenotype), and performance measures, with prevalence ranging from approximately 7% to 46%. Frailty predicted faster accrual of organ damage (per 0.05 increase in SLICC-FI, adjusted IRR 1.20, 95% CI 1.14-1.27) and higher healthcare utilization (adjusted IRR 1.21, 95% CI 1.13-1.30). In the largest cohort (n=1,566), frailty was associated with increased mortality (adjusted HR 4.37, 95% CI 2.67-7.17) and showed a dose-response relationship. Frailty was also consistently linked to worse physical function, greater disability, and poorer HRQoL. Frailty is common in SLE and independently identifies patients at higher risk of adverse outcomes. Standardized definitions and longitudinal studies are needed to support risk stratification and targeted interventions.


  • Metabolomics in systemic lupus erythematosus: A systematic review and meta-analysis

    by Susana Barrera-Hernández, Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Blanca Guadalupe Baez-Duarte, Irma Zamora-Ginez, Edith Ramírez-Lara, Álvaro José Montiel-Jarquin, Máximo Alejandro García-Flores, Socorro Méndez-Martínez


  • Prevalence, incidence, and mortality of autoimmune diseases among adolescents and young adults in Mexico: an analysis based on the global burden of disease study 2021

    by Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Fernanda Solis-Mendoza, José Luis Gálvez-Romero, Edith Ramírez-Lara, Marco Alejandro Trinidad González, Brenda Michel Silva Juárez, Máximo Alejandro García Flores, Socorro Méndez-Martínez

    This nationwide analysis quantified the contemporary and future burden of six autoimmune diseases (ADs)—rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), asthma, and psoriasis—among Mexican adolescents and young adults (AYAs, 10–24 years) using the Global Burden of Disease 2021 database. Age-standardised prevalence (ASPR), incidence (ASIR), and mortality (ASMR) rates for 2021 were calculated by direct standardisation to the GBD world population; 1990–2021 temporal patterns were explored through Joinpoint regression to derive average annual percentage change, and Box-Jenkins ARIMA models projected trends up to 2035, incorporating diagnostic-capacity covariates. In 2021, RA had the greatest burden (ASPR 45.7/100,000; ASIR 9.1), with a striking female predominance and north-south variability. Although IBD remained infrequent, its mortality rose in states where colonoscopy access expanded, suggesting detection bias yet underscoring rising severity. MS prevalence and incidence climbed steadily, particularly among young women in urbanised regions. T1DM maintained the highest absolute caseload and incidence but showed slowly declining rates; nevertheless, ASMR inched upward, reflecting suboptimal metabolic control. Asthma, while still the most prevalent AD, exhibited a modest downward trajectory, whereas psoriasis incidence was stable, yet prevalence remained substantial, signalling chronic disease accumulation. Forecasts predict moderate growth in RA and MS cases, relative plateauing of IBD, asthma, and psoriasis, and continued contraction of T1DM incidence with a slight mortality uptick. Persistent geographic and sex-related inequities highlight the necessity for region-specific prevention strategies, earlier immune-modulating therapy, and equitable access to specialised care to mitigate the projected AD burden in Mexican AYAs.


  • Systemic lupus erythematosus in critical care: A systematic review of ICU outcomes and management

    by Edith Ramírez-Lara, Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Miguel Ángel Saavedra-Salinas, Ivet Etchegaray-Morales, Jorge Ayón-Aguilar, Álvaro José Montiel-Jarquín, Socorro Martínez-Méndez


  • Health‐Related Quality of Life in Patients With Systemic Autoimmune Rheumatic Diseases (SARD) and Post‐COVID Syndrome: A Case‐Control Study

    by Pamela Munguía‐Realpozo, Claudia Mendoza‐Pinto, Sandra Ibañez‐Ovando, Ana Luisa Roco‐Zúñiga, Jesús Texis‐Ramírez, Juan Serrano‐Ramírez, Ivet Etchegaray‐Morales

    Objective: To assess the prevalence and characteristics of the post‐COVID syndrome and its effect on the health‐related quality of life (HRQOL) of COVID‐19‐recovered patients with SARD. Methods: This cross‐sectional study included patients over 18 years old with systemic autoimmune rheumatic diseases (SARDs) in addition to sex‐ and age‐matched controls without SARDs who tested positive for SARS‐CoV‐2. Sociodemographic variables and clinical data related to the infection and its severity were collected using EuroQol‐5 dimensions‐5 levels (EQ‐5D‐5L) and EuroQol‐visual analogue scales (EQ‐VAS). Results: We included 58 patients with SARD and 116 controls. Post‐COVID syndrome was observed in 39 (67.2%) of SARD patients and 86.2% of the controls ( p < 0.001). The most frequent post‐COVID syndrome symptoms were fatigue (74.4%), anosmia (35.9%), and dysgeusia (28.2%). The EQ‐VAS score was lower in patients with SARD than in controls (62.4 ± 18.6 vs. 80.9 ± 7.3; p < 0.001). Similarly, SARD patients with post‐COVID syndrome had lower EQ‐VAS than those without post‐COVID syndrome VAS = 62.4 ± 18.6 versus 75.9 ± 14.9; p = 0.011. Conclusions: We found that 67.2% of patients with SARDs affected by COVID‐19 presented with persistent symptoms. However, patients with SARD showed significantly lower HRQL than patient controls.

  • Open Access

    Prevalence, Incidence, and Mortality of Autoimmune Diseases Among Adolescents and Young Adults in Mexico: An Analysis Based on the Global Burden of Disease Study 2021

    by Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Fernanda Solis-Mendoza, José Luis Gálvez-Romero, Edith Ramírez-Lara, Marco Alejandro Trinidad González, Brenda Michel Silva Juárez, Máximo Alejandro García Flores, Socorro Méndez-Martínez

    Autoimmune diseases (ADs) pose a significant health burden among adolescents and young adults (AYAs) in Mexico. However, comprehensive national epidemiological data remain limited. This study evaluates the prevalence, incidence, and mortality of six major AD: rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), asthma, and psoriasis, utilizing data from the Global Burden of Disease Study 2021. Age-standardized rates were calculated through direct standardization using the GBD 2021 world standard population. Temporal trends from 1990 to 2021 were analyzed via Joinpoint regression, which determined each condition’s average annual percentage change (AAPC). Additionally, an ARIMA model was employed to forecast trends for the period from 2022 to 2035. In 2021, RA exhibited an age-standardized prevalence rate (ASPR) of 45.67, an incidence rate (ASIR) of 9.07, and a mortality rate (ASMR) of 0.02 per 100,000 inhabitants, with a marked female predominance and notable regional disparities. IBD showed low prevalence and incidence but a rising mortality trend, particularly in areas with enhanced diagnostic capacities. MS demonstrated increasing prevalence and incidence, especially among females. T1DM presented high prevalence and incidence, with declining trends over time accompanied by a gradual rise in mortality. Asthma remained highly prevalent despite overall declining trends, while psoriasis maintained a stable incidence with a considerable prevalence among AYAs. The findings highlight significant regional and sex-related disparities in the burden of ADs among Mexican AYAs. Forecasting analyses predict moderate increases in RA and MS, stability in IBD, asthma, and psoriasis, and a decline in T1DM prevalence and incidence, albeit with a slight increase in mortality. These results emphasize the urgent need for targeted public health interventions, improved diagnostic strategies, and equitable healthcare provision to mitigate the future impact of ADs in this vulnerable population.